Processa Pharma Files 8-K, Confirms Nasdaq Listing

TL;DR

**Processa Pharma filed a routine 8-K, confirming its Nasdaq listing and compliance.**

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on January 19, 2024, primarily to disclose general corporate information and confirm its registration on the Nasdaq Capital Market under the trading symbol PCSA. This filing, while routine, indicates the company is maintaining its public listing and compliance. For investors, this matters because it confirms the company's continued presence on a major exchange, which is crucial for liquidity and visibility, though it doesn't announce any new material financial or operational events.

Why It Matters

This filing confirms Processa Pharmaceuticals' ongoing compliance with SEC regulations and its listing on the Nasdaq Capital Market, which is fundamental for investor access and trading liquidity.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain information that introduces new financial or operational risks.

Analyst Insight

This filing is administrative and does not provide new material information for investment decisions; investors should look for filings detailing financial results, clinical trial updates, or strategic developments for actionable insights.

Key Numbers

• $0.0001 — Par value per share (The stated par value of Processa Pharmaceuticals' common stock.)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Nasdaq Capital Market (company) — the exchange where Processa Pharmaceuticals' common stock is registered
• PCSA (other) — the trading symbol for Processa Pharmaceuticals' common stock
• January 19, 2024 (date) — the date of the earliest event reported in the 8-K
• $0.0001 (dollar_amount) — the par value of Processa Pharmaceuticals' common stock

Forward-Looking Statements

• Processa Pharmaceuticals will continue to be listed on the Nasdaq Capital Market. (Processa Pharmaceuticals, Inc.) — high confidence, target: Ongoing

FAQ

Filing Documents

• form8-k.htm (8-K) — 37KB
• ex99-1.htm (EX-99.1) — 17KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• 0001493152-24-002983.txt ( ) — 242KB
• pcsa-20240119.xsd (EX-101.SCH) — 3KB
• pcsa-20240119_lab.xml (EX-101.LAB) — 33KB
• pcsa-20240119_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (Address of Principal Executive Offices, Including Zip Code) ( 443 ) 776-3133 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation FD Disclosure. On January 19, 2024, Processa Pharmaceuticals, Inc. (the "Company") issued a press release announcing the expansion of NGC-Cap program into advanced or metastatic breast cancer and that the FDA has agreed that existing data and studies can be used to support the Phase 2 breast cancer trial design. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Press release announcing the expansion of NGC-Cap program into advanced or metastatic breast cancer. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on January 19, 2024. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR